Trial | NCT00162799  Report issue

Title

Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    triflusal ...

  • Study Participants

    30
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.
Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled.

Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days

Washout period: 30 days
Study Started
Jul 31
2002
Study Completion
Dec 31
2004
Last Update
Jun 23
2006
Estimate

Drug Triflusal (DCI)

Criteria 

Inclusion Criteria:

Ages 35 to 60 years old
No Results Posted